SCShih-Chieh Chang

Shih-Chieh Chang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Shih-Chieh Chang has a total of 34 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Esophageal neuroendocrine tumor with initial presentation as painless forehead and neck masses

    by Yen-Po Chin, Wei-Fu Lai, Meng-Ting Chiang, Shih-Chieh Chang

    Esophageal neuroendocrine tumors (NETs) are a rare type of esophageal tumor which are usually positive for chromogranin A, synaptophysin, and CD56 in tumor immunohistochemical staining. The most common symptoms of esophageal NETs are gastrointestinal symptoms such as dysphagia and/or abdominal discomfort. While esophageal NETs have the potential for distant metastasis, there have only been a few reports of brain metastasis originating from esophageal NET. We report the case of a 60-year-old Taiwanese female who initially presented with a 1 month history of painless forehead and bilateral neck masses. She did not complain of any other symptoms, which complicated the diagnosis. Chest and abdominal computed tomography were arranged for a thorough evaluation, and a paraesophageal lesion as well as multiple metastases in the liver, bilateral adrenal glands, and bone were found. Panendoscopy and pathology confirmed the diagnosis of an esophageal NET. Best supportive care. The clinical course of this case deteriorated drastically, and she died of tumor progression 10 days after the diagnosis had been made. To the best of our knowledge, this is the first article in the literature to report a case of esophageal NET whose initial presentation was painless forehead and bilateral neck masses. Clinicians should be aware of the early signs and symptoms of esophageal NET to allow for a prompt diagnosis.


  • Clinical analysis of NSCLC patients reveals lack of association between EGFR mutation and TET1 downregulation

    by J-I Lai, Y-C Lai, Y-C Chen, N-K Wang, J-N Pan, W-S Wang, S-C Chang

    Lung cancer is one of the leading causes of death from cancer worldwide, with a poor prognosis in advanced cases. In the past decade, epidermal growth factor receptor (EGFR) inhibitors have shown significant efficacy towards treatment for EGFR mutant lung cancer. Expanding our knowledge of oncogenic EGFR signaling pathways is therefore of highly importance for the cancer field. Recently it has been proposed that mutant EGFR transcriptionally silences the TET1 (ten–eleven translocation methylcytosine dioxygenase 1) gene in cellular and animal models of lung cancer. Since TET1 is a known DNA demethylase, EGFR-mediated TET1 silencing therefore downregulates demethylation of tumor suppressor genes, which then leads to tumor growth inhibition, potentiating the role of TET1 as a tumor suppressor gene in NSCLC. In our study, we examined the role of EGFR-TET1 silencing in NSCLC patient samples. By independently analyzing the TCGA (The Cancer Genome Atlas) NSCLC data set as well as a cohort of patient samples from our hospital and a data set from publicly deposited databases, we did not observe the aforementioned mutant EGFR silencing of TET1. Conversely, in our cohort, TET1 expression levels were significantly elevated in EGFR mutant samples (P=0.007). Patients with higher TET1 levels showed a trend of better response rates to EGFR inhibitors compared to low TET1 staining levels, although the result was not significant (P=0.08). Furthermore, we did not observe a correlation between TET1 expression levels and patient survival. We conclude that while oncogenic EGFR suppression of TET1 is established in cellular and animal models of lung cancer, its role in patient outcome and prognosis remains inconclusive and warrants further investigation.


  • Open Access

    Risk factors in patients with AFB smear-positive sputum who receive inappropriate antituberculous treatment

    by Cheng-Yu Chang, Mei-Kang Yuan, Yuan-Ming Lee, Shih-Chieh Chang, Li-Cho Hsu, Shin-Lung Cheng, Jen-Yee Hong, Shu-Ju Chang

    Peer reviewed article authored by (Chang CY, Hong JY, Yuan MK, Chang SJ, Lee YM, Chang SC, Hsu LC, Cheng SL). Read article or submit your manuscript for publishing.


  • The value of positron emission tomography in early detection of lung cancer in high‐risk population: a systematic review

    by Cheng‐Yu Chang, Shu‐Ju Chang, Shih‐Chieh Chang, Mei‐Kang Yuan

    Background:  Early detection trials with chest radiography and sputum cytology were ineffective in decreasing lung cancer mortality. The advent of low‐dose spiral chest computed tomography (LDCT) provided clinicians with a new tool that could be with early diagnosis; however, this also raised significant concerns regarding the systematic use of LDCT with its high false‐positive rate for benign nodules. At this time, there is limited information about the true role of PET (positron emission tomography) for early detection of lung cancer.Methods:  We used systematic methods, including Preferred Reporting Items for Systematic reviews and Meta‐Analyses statement, to identify relevant studies, assess study eligibility, evaluate study methodological quality, and summarize findings regarding diagnostic accuracy and outcome.Results:  In total, only seven eligible studies were selected from 82 potentially relevant studies. The sensitivity of 18F‐FDG‐PET for the detection of T1 lung cancers ranged between 68% and 95%. The rate of detection tended to be lower for carcinoid tumors, adenocarcinoma and bronchoalveolar cell carcinomas. FDG‐PET using SUV (standardized uptake value) level can predict the outcome of the screening detected lung cancer. A combination of FDG‐PET and LDCT may improve screening for lung cancer in high‐risk patients.Conclusions:  PET or PET/CT may be used as a useful tool for early detection of lung cancer in high‐risk population based on the existing information. However, there is still limited information with regards to evidence of survival benefits from PET screening in high‐risk patients.Please cite this paper as: Chang C‐Y, Chang S‐J, Chang S‐C and Yuan M‐K. The value of positron emission tomography in early detection of lung cancer in high‐risk population: a systematic review. Clin Respir J 2013; 7: 1–6.


  • Imaging patterns and prognosis of patients with gefitinib-related interstitial lung disease

    by M.-K. Yuan, C.-Y. Chang, S.- C. Chang, G.- J. Tang, Y.-F. Wei, Y.-C. Liu, C.-J. Yu

    We aimed to summarize the imaging findings of 25 patients with gefitinib-related interstitial lung disease (ILD), and identify the factors related to prognosis of gefitinib-related ILD in patients with non-small-cell-lung cancer. Diagnosis of gefitinib-induced ILD by at least two chest radiologists was based on a review and analysis of the chest radiography and CT findings plus clinical data in the medical records. All patients were diagnosed with Stage III - IV non-small-cell carcinoma (adenocarcinoma (n = 24), bronchioalveolar cell carcinoma (n = 1)) and essential clinical data such as gefitinib as first-line use and survival status were recorded and analyzed to determine whether these were prognosis predictors. The imaging findings were classified into four patterns according to the previous largest study in Japan. The 25 chest radiographs were classified as Pattern A (n = 8), Pattern B (n = 3), Pattern C (n = 6), and pattern D (n = 8). Likewise the 23 CT images were classified as pattern A (n = 8; 34.8%), B (n = 3; 13%), C (n = 5; 21.7%), and D (n = 7; 30.4%). The mortality rate was significantly higher in patients with pattern D than in patients with the other patterns. Pattern D imaging findings were also significantly correlated with non first-line use of gefitinib (p = 0.007). We found an increase in mortality rate in patients with gefitinib associated ILD/pattern D compared to other radiological patterns. Familiarity with these imaging patterns can facilitate early and accurate diagnosis and help physicians gauge clinical prognosis of gefitinib-related ILD.


  • Obturator Hernia in an Elderly Woman Presenting with Aspiration Pneumonia and Respiratory Failure

    by Jia-Ming Wang, Po-Chou Lin, Wei-Chan Lin, Jiun-I Lai, Yi-Chun Lai, Shih-Chieh Chang

    Obturator hernia is a rare but important cause of intestinal obstruction. The mortality rate is high if the diagnosis is not made early and surgical intervention is delayed. We report an 88-year-old female patient who presented with aspiration pneumonia and respiratory failure. She did not have nausea/vomiting and physical examination was unremarkable. She was fed through a nasogastric tube, but no gastric emptying was noted. An abdominal/pelvic computed tomograpy (CT) scan performed 5 days after the presentation revealed a left incarcerated obturator hernia. Emergency laparotomy was performed and the patient eventually recovered. This case reminds us that aspiration pneumonia may be the presenting feature of obturator hernia and a clue to its early diagnosis.

  • Open Access

    The Role of Epidermal Growth Factor Receptor Mutations and Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in the Treatment of Lung Cancer

    by Shih-Chieh Chang, Cheng-Yu Chang, Jin-Yuan Shih

    Lung cancer is the leading cause of cancer-related deaths worldwide. Non-small-cell lung cancer (NSCLC) cases comprise approximately 85% of the lung cancer cases. Before the era of target therapy, platinum-based doublet chemotherapy only led to a median survival of 8–9 months and a one-year survival of 30%–40% in patients with advanced NSCLC. In July 2002, gefitinib, a small-molecule epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI), was approved for the treatment of patients with advanced NSCLC in Japan. After the widespread use of gefitinib in the treatment of NSCLC, there have been many new studies regarding the association between the clinical anticancer efficacy of gefitinib and the somatic EGFR mutation status in patients with NSCLC. This article summarizes the role of EGFR mutations in lung cancer and the use of EGFR antagonists in the treatment of lung cancer and its associated adverse effects.


  • Conservative Treatment of Severe Tracheal Laceration After Endotracheal Intubation

    by Cheng-Yu Chang, Shih-Lung Cheng, Shih-Chieh Chang

    Endotracheal intubation can lead to iatrogenic trauma to the upper airways. Superficial mucosal tears in the mouth, pharynx, or larynx are common and can cause secondary infection and acute respiratory distress due to massive air leak. We report a patient who sustained a severe 5-cm tracheal laceration and subcutaneous emphysema after intubation. She was successfully weaned from the ventilator after adjustment of the endotracheal cuff, therapy with broad-spectrum antibiotics, and continuous airway humidification.


  • Acute Mesenteric Infarction Associated with Atrial Fibrillation

    by Jia-Ming Wang, Shih-Chieh Chang

    Images in Clinical Medicine from The New England Journal of Medicine — Acute Mesenteric Infarction Associated with Atrial Fibrillation